Investigation Of The Low Dose UV G2 Phase Checkpoint And Its Potential Exploitation In The Treatment Of Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$35,085.00
Summary
The research aims to indentify the role UV exposure contributes to the development of melanoma and if this knowledge can be used to develop new methods in the prevention and treatment of this disease
Clinical And Molecular Analyses Of Nodular Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$130,904.00
Summary
There have been very recent advances in our understanding of the biology of melanoma that are now poised to have major impacts in the outcome of patients with this disease. The nodular subtype of melanoma contributes disproportionately to mortality from melanoma. By using the latest molecular techniques to study these melanomas I will identify causative factors, diagnostic features and molecular profiles associated with these poor-prognosis melanomas leading to new approaches in the prevention, ....There have been very recent advances in our understanding of the biology of melanoma that are now poised to have major impacts in the outcome of patients with this disease. The nodular subtype of melanoma contributes disproportionately to mortality from melanoma. By using the latest molecular techniques to study these melanomas I will identify causative factors, diagnostic features and molecular profiles associated with these poor-prognosis melanomas leading to new approaches in the prevention, early detection and treatment of these melanomas.Read moreRead less
Study Of C-KIT Mutations In Familial Gastrointestinal Stromal Tumours, Melanoma And A Novel Form Of Waardenburg Syndrome
Funder
National Health and Medical Research Council
Funding Amount
$68,378.00
Summary
The primary aim of this research project is to study mutations in a cancer causing gene called c-KIT. We seek to identify tumour characteristics which are predictive for the presence of particular types of c-KIT mutations in melanomas and gastrointestinal stromal tumours. The detection of tumours harbouring these mutations will help in the treatment of cancer sufferers because this group of patients have been shown to respond very well to a class of drugs known as tyrosine kinase inhibitors.